A head-to-head comparison of periprocedural coagulability under anticoagulation with rivaroxaban versus dabigatran in patients undergoing ablation of atrial fibrillation.

@article{Sairaku2013AHC,
  title={A head-to-head comparison of periprocedural coagulability under anticoagulation with rivaroxaban versus dabigatran in patients undergoing ablation of atrial fibrillation.},
  author={Akinori Sairaku and Yukihiko Yoshida and Monami Ando and Haruo Hirayama and Yukiko Nakano and Yasuki Kihara},
  journal={Clinical drug investigation},
  year={2013},
  volume={33 11},
  pages={847-53}
}
BACKGROUND AND OBJECTIVES Two new oral anticoagulants, rivaroxaban and dabigatran, with no need for anticoagulation monitoring, are available for patients with atrial fibrillation (AF). We aimed to compare their anticoagulant effects and safety when used during the AF ablation periprocedural period. METHODS Patients undergoing AF ablation were randomly assigned to receive rivaroxaban 15 mg once daily (N = 30) or dabigatran 110 mg twice daily (N = 30). Rivaroxaban was withheld on the morning… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

Similar Papers

Loading similar papers…